Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some patients with HCC initially respond to sorafenib, but eventually succumb to the disease, indicating that the acquired resistance to sorafenib reduces its beneficial effects. No alternative drugs are available aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Peng, Li, Hali, Jiang, Xian, Zhai, Bo, Tan, Gang, Zhao, Dali, Qiao, Haiquan, Liu, Bing, Jiang, Hongchi, Sun, Xueying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527443/
https://www.ncbi.nlm.nih.gov/pubmed/28164434
http://dx.doi.org/10.1002/1878-0261.12039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527443/
https://www.ncbi.nlm.nih.gov/pubmed/28164434
http://dx.doi.org/10.1002/1878-0261.12039

Ejemplares similares